BioScrip (NASDAQ: BIOS) is one of 15 publicly-traded companies in the “Hospitals, Clinics & Primary Care Services” industry, but how does it weigh in compared to its rivals? We will compare BioScrip to similar businesses based on the strength of its earnings, institutional ownership, analyst recommendations, risk, profitability, dividends and valuation.
Volatility and Risk
BioScrip has a beta of 0.27, suggesting that its stock price is 73% less volatile than the S&P 500. Comparatively, BioScrip’s rivals have a beta of 0.83, suggesting that their average stock price is 17% less volatile than the S&P 500.
This is a summary of recent ratings and target prices for BioScrip and its rivals, as provided by MarketBeat.com.
||Strong Buy Ratings
BioScrip currently has a consensus target price of $3.83, suggesting a potential upside of 20.55%. As a group, “Hospitals, Clinics & Primary Care Services” companies have a potential upside of 16.36%. Given BioScrip’s stronger consensus rating and higher possible upside, equities research analysts clearly believe BioScrip is more favorable than its rivals.
This table compares BioScrip and its rivals’ net margins, return on equity and return on assets.
||Return on Equity
||Return on Assets
Institutional & Insider Ownership
84.6% of BioScrip shares are held by institutional investors. Comparatively, 69.0% of shares of all “Hospitals, Clinics & Primary Care Services” companies are held by institutional investors. 0.8% of BioScrip shares are held by company insiders. Comparatively, 10.4% of shares of all “Hospitals, Clinics & Primary Care Services” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares BioScrip and its rivals gross revenue, earnings per share and valuation.
BioScrip’s rivals have higher revenue and earnings than BioScrip. BioScrip is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
BioScrip beats its rivals on 7 of the 13 factors compared.
BioScrip, Inc. is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment. The Company operates through approximately 70 service locations in over 30 states. The Company offers home infusion services to provide clinical management services and the delivery of prescription medications. The Company provides services in coordination with, and under the direction of, the patient’s physician. The Company’s multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Its platform provides service capabilities to deliver clinical management services that offer patients a community-based and home-based care environment.
Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.